Predictors of pathological complete response to neoadjuvant ...
Recommend Documents
intraperitoneal (IP) perfusion chemotherapy with irinotecan. (100 mg/m2) was ..... and Raynard B: Optimization of hyperthermic intraperitoneal chemotherapy ...
Pathological complete response after neoadjuvant chemotherapy for rectal cancer with synchronous multiple liver metastases: a report of an unusual case.
Sep 9, 2010 - and capecitabine without severe toxicities except grade 2 diarrhea near the completion of cycle 3 requiring dis- continuation of capecitabine.
chemotherapy regimens, with or without capecitabine (X). Patients with operable, invasive breast cancer [2.0 cm in diameter, were randomized to AT?CMF, AT?
The benefit of primary systemic (neoadjuvant) chemo- therapy (PSC) in the treatment of breast cancer, and the association of a pathologic complete response ...
Sep 6, 2007 - Abstract FOLFOX-4 (folinic acid/5-fluorouracil/oxaliplatin) chemotherapy is used to treat patients with colorectal liver metastases. We aimed to ...
FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. ... pCR, which
This guidance is intended to assist applicants in designing trials to support marketing approval of drugs and biological
Center, Philadelphia, PA; 3Department of Nuclear Medicine, Fox Chase Cancer ... Biostatistics, Fox Chase Cancer Center, Philadelphia, PA; 5Department of ...
Estrada1, Carlos López-Graniel3, Aaron González-Enciso3, David Cantú3, ... [email protected]; Jaime de la Garza - [email protected]; Alfonso Dueñas- ..... 22. Kim DS, Moon H, Hwang YY, Cho SH: Preoperative adjuvant.
Apr 19, 2016 - 1Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, ...
Rectal cancer is the third most common cancer after lung ... Methods: The retrospective case series was done at the Aga Khan University Hospital, Karachi, and ...
Feb 26, 2017 - 1 Department of Medicine, Division of Hematology/Oncology, Drexel ... 3Department of Pathology & Laboratory Medicine, Drexel University ...
metastases that had a marked response to SOX plus BV and achieved a pCR following radical liver resection. Case report. A 63-year-old man was referred to a ...
Dec 12, 2014 - Introduction. Neoadjuvant chemoradiotherapy and total mesorectal excision are considered the standard treatment for locally advanced rectal ...
May 17, 2016 - 5Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
May 17, 2016 - Daniel C. McFarland,1 Jessica Naikan,2 Mariya Rozenblit,3 John Mandeli,4 ... ceptin (NOAH) trial demonstrated an absolute improvement.
Correspondence: Jin Hee Kim, MD, PhD, Department of Radiation Oncology, Dongsan Medical Center, ... Young Ki Oh, PhD2, Sung Gyu Baek, MD, PhD3.
therapy in borderline resectable or locally advanced pancreatic cancer. ... Keywords: FOLFIRINOX, Pancreatic cancer, Complete pathological response, ...
Received: 07 April 2016; Accepted: 21 May 2016. DOI : 10.1186/s40792-016-0178-x. Cite this article as: Arai, K., Fukumoto, T., Tanaka, M. et al. surg case rep ...
... Dijon, France; 6Department of Pathology, Jean Perrin Cancer Center, F-63011 ...... Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001).
Jun 30, 2007 - with Advanced Breast Cancer (ABC) in the developing ... female patients registered at the Institute of Nuclear Medicine and Oncology, Lahore, Pakistan, between 1st July ..... inflammatory breast cancer with fixed perioperative.
Dec 28, 2013 - Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus. Fergus Noble, Luke Nolan, Adrian C Bateman, ...
SLX4 rs714181. A. 0.125. 0.154. 0.197. 21. GRIK1 rs363599. A. 0.023. 0.090. 0.255. 21. GRIK1 rs457531. T. 0.117. 0.077. 1.000. â P-value for HWE Ï2 test ...
Predictors of pathological complete response to neoadjuvant ...
Jun 4, 2015 - Cancer Center between 2006 and 2010, to identify patients ..... study were treated at a high-volume, NCI-designated compre- hensive cancer ...
MOLECULAR AND CLINICAL ONCOLOGY 3: 1117-1122, 2015
Predictors of pathological complete response to neoadjuvant chemotherapy in stage II and III breast cancer: The impact of chemotherapeutic regimen IHEOMA Y. NWAOGU1, OLUWADAMILOLA M. FAYANJU1, DONNA B. JEFFE2,3 and JULIE A. MARGENTHALER3 1
Department of Surgery, 2Division of General Medical Sciences, Department of Medicine, 3The Alvin J. Siteman Cancer Center, Barnes‑Jewish Hospital, Washington University School of Medicine, St. Louis, MO 63110, USA Received May 7, 2015; Accepted June 4, 2015 DOI: 10.3892/mco.2015.579
Abstract. In this study, we sought to determine the predictors of pathological complete response (pCR) and compare the chemotherapeutic regimens administered to breast cancer patients with and those without pCR. We retrospectively reviewed the data of 879 patients treated at the Alvin J. Siteman Cancer Center between 2006 and 2010, to identify patients who were diagnosed with primary stage II or III breast cancer and received neoadjuvant chemotherapy. Patients who received only neoadjuvant endocrine therapy were considered to be ineligible. Patient, tumor, and treatment characteristics, including type of chemotherapy, were compared between patients who did and those who did not achieve pCR using Chi‑square or Fisher's exact tests and multivariate logistic regression analysis. Two‑sided P‑values of
